KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teladoc Health (TDOC) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Teladoc Health (TDOC) over the last 13 years, with Q3 2025 value amounting to $726.2 million.

  • Teladoc Health's Cash & Equivalents fell 4161.36% to $726.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $726.2 million, marking a year-over-year decrease of 4161.36%. This contributed to the annual value of $1.3 billion for FY2024, which is 1554.29% up from last year.
  • Per Teladoc Health's latest filing, its Cash & Equivalents stood at $726.2 million for Q3 2025, which was down 4161.36% from $679.6 million recorded in Q2 2025.
  • In the past 5 years, Teladoc Health's Cash & Equivalents registered a high of $1.3 billion during Q4 2024, and its lowest value of $679.6 million during Q2 2025.
  • Moreover, its 5-year median value for Cash & Equivalents was $899.6 million (2022), whereas its average is $955.8 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first skyrocketed by 4176.5% in 2021, then tumbled by 4161.36% in 2025.
  • Over the past 5 years, Teladoc Health's Cash & Equivalents (Quarter) stood at $893.5 million in 2021, then grew by 2.76% to $918.2 million in 2022, then increased by 22.38% to $1.1 billion in 2023, then increased by 15.54% to $1.3 billion in 2024, then tumbled by 44.06% to $726.2 million in 2025.
  • Its last three reported values are $726.2 million in Q3 2025, $679.6 million for Q2 2025, and $1.2 billion during Q1 2025.